Apolipoprotein B/A1 and risk of cardiovascular disease.

摘要

In recent years, whether measurements of apolipo-proteins are better than lipoproteins for risk prediction of cardiovascular disorders, and whether the apolipoprotein B/Al ratio should be the preferred lipid measurement in the future has been debated. In today's Lancet, new fuel to this discussion has been added by the INTERHEART study, a large international case-control study about risk factors for myocardial infarction with more than 9000 patients.1 The investigators found that the apolipoprotein B/Al ratio was better than any other conventional lipid measure, including other ratios, with a population attributable risk of 54% for the apolipoprotein B/Al ratio compared with 37% for the best conventional lipid measure (LDL-cholesterol/HDL-cholesterol, p<00001).